US FDA approves Merck's RSV antibody for infants
1. FDA approved Merck's antibody shot for infants against RSV. 2. Approval could enhance Merck's market position in pediatric healthcare.
FAQ
Why Bullish?
FDA approvals typically boost stock prices. Historical approvals in biopharma often lead to positive market reactions, which could similarly benefit MRK.
How important is it?
Approval for a preventive measure in pediatrics opens significant revenue streams for Merck, increasing its strategic market position.
Why Short Term?
Market reactions are immediate post-approval, but sustained impact depends on sales performance. Similar products usually see initial sales spikes, affecting stock within months.